The first radiology triage modality to garner a Breakthrough Device Designation from the FDA, Annalise-Obstructive Hydrocephalus has reported sensitivity and specificity rates of 97.5 percent and 95.3 percent respectively.
The Centers for Medicare and Medicaid Services (CMS) will provide a new technology add-on payment (NTAP) in 2025 for the use of the artificial intelligence (AI) software Annalise-Obstructive Hydrocephalus (OH), which facilitates triage of suspected OH cases based on an analysis of brain computed tomography (CT) cans.
While the clinical presentation of OH has similar characteristics to other neurological conditions, the potentially life-threatening OH requires urgent detection and treatment. Annalise-Obstructive Hydrocephalus identifies suspicious findings of OH within minutes of assessing non-contrast brain CT scans, according to Annalise.ai, the manufacturer of the AI software.
The company emphasized that Annalise-Obstructive Hydrocephalus, which garnered the FDA’s Breakthrough Device Designation in 2023, has an area under the curve (AUC) of 98.7 percent, a sensitivity rate of 97.5 percent and a specificity rate of 95.3 percent for OH detection.
“Patients with obstructive hydrocephalus can deteriorate rapidly if not promptly identified, evaluated, and treated. Annalise-OH will help care teams identify these patients faster, consult with their neurosurgeon, and reduce the chance that they suffer from severe complications,” noted Aaron Yengo-Kahn, M.D., a neurosurgeon based in Orange, Calif.”
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.